TY  - JOUR

T1  - Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.

JO  - Pharmacoeconomics

UR  - https://eprints.whiterose.ac.uk/id/eprint/101613

UR  - http://dx.doi.org/10.1007/s40273-016-0412-1

PY  - 2016/08/01

AU  - Graham J

AU  - McBride D

AU  - Stull D

AU  - Halliday A

AU  - Alexopoulos ST

AU  - Balp MM

AU  - Griffiths M

AU  - Agirrezabal I

AU  - Zuberbier T

AU  - Brennan A

ED  - 

DO  - DOI: 10.1007/s40273-016-0412-1

PB  - Springer Verlag

VL  - 34

IS  - 8

SP  - 815

EP  - 827

Y2  - 2025/11/01

ER  -